Explore Ultromics’ blog with tons of articles and information to further understand AI-enabled cardiovascular imaging solutions.
Learn how Dr Schuster at University Cleveland Hospitals discusses his motives for using AI to detect HFpEF and the process of implementing AI into clinical practice.
Learn how AI-driven echocardiography is revolutionizing detection of cardiac amyloidosis. Discover the impact of faster, more accurate detection for improved patient care.
Explore challenges in cardiac amyloidosis diagnosis, from delays to misdiagnoses, and how AI could improve early detection and patient outcomes.
Ross Upton CEO and Founder of Ultromics explores the challenges and strategies for securing reimbursement for AI-driven echocardiography, essential for market success and patient care.
Ultromics co-founder and CMO Professor Paul Leeson shares his opinion on the growing impact AI is having on heart failure detection.
Uncover the causes, symptoms, and treatments for cardiac amyloidosis, offering hope and insights into managing this complex condition
"Learn how Ultromics secured four FDA clearances and two Breakthrough Designations in just four years. Explore our journey of innovation!"
SGLT2 inhibitors are emerging as a new and effective therapeutic option for patients with heart failure with preserved ejection fraction (HFpEF)
In honor of World Heart Day on September 29, we're diving into the world of cardiovascular diagnostics with top advances in echocardiography this last year.
Sign-up to hear about the latest news.
Sign up to newsletter
cases processed
.jpg?noresize)
